Cargando…

High-throughput drug screening allowed identification of entry inhibitors specifically targeting different routes of SARS-CoV-2 Delta and Omicron/BA.1

The Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) has continuously evolved, resulting in the emergence of several variants of concern (VOCs). To study mechanisms of viral entry and potentially identify specific inhibitors, we pseudotyped lentiviral vectors with different SARS-CoV...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuzikov, Maria, Woens, Jannis, Zaliani, Andrea, Hambach, Julia, Eden, Thomas, Fehse, Boris, Ellinger, Bernhard, Riecken, Kristoffer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Masson SAS. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108036/ https://www.ncbi.nlm.nih.gov/pubmed/35643072 http://dx.doi.org/10.1016/j.biopha.2022.113104

Ejemplares similares

A High-Throughput HIV-1 Drug Screening Platform, Based on Lentiviral Vectors and Compatible with Biosafety Level-1
por: Ellinger, Bernhard, et al.
Publicado: (2020)

Digital PCR to quantify ChAdOx1 nCoV-19 copies in blood and tissues
por: Badbaran, Anita, et al.
Publicado: (2021)

Omicron entry route
por: Pia, Luisanna, et al.
Publicado: (2022)

How to package and SEND mRNA: a novel “humanized” vector system based on endogenous retroviruses
por: Riecken, Kristoffer, et al.
Publicado: (2021)

Efficient Pseudotyping of Different Retroviral Vectors Using a Novel, Codon-Optimized Gene for Chimeric GALV Envelope
por: Mirow, Manuela, et al.
Publicado: (2021)

In-vivo RGB marking and multicolour single-cell tracking in the adult brain
por: Gomez-Nicola, Diego, et al.
Publicado: (2014)

A new system for parallel drug screening against multiple-resistant HIV mutants based on lentiviral self-inactivating (SIN) vectors and multi-colour analyses
por: Prokofjeva, Maria M, et al.
Publicado: (2013)

A booster of Delta-Omicron RBD-dimer protein subunit vaccine augments sera neutralization of Omicron sub-variants BA.1/BA.2/BA.2.12.1/BA.4/BA.5
por: Duan, Minrun, et al.
Publicado: (2023)

SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta
por: van Doremalen, Neeltje, et al.
Publicado: (2022)

Rapid, high throughput, automated detection of SARS-CoV-2 neutralizing antibodies against Wuhan-WT, delta and omicron BA1, BA2 spike trimers
por: Cheedarla, Narayanaiah, et al.
Publicado: (2023)

Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants
por: Neerukonda, Sabari Nath, et al.
Publicado: (2022)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Understanding spatiotemporal symptom onset risk of Omicron BA.1, BA.2 and hamster-related Delta AY.127
por: Tong, Chengzhuo, et al.
Publicado: (2022)

Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa
por: Wolter, Nicole, et al.
Publicado: (2022)

Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5
por: Bormann, Maren, et al.
Publicado: (2023)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Long-term humoral response following Delta and Omicron BA.1 co-infection
por: Saade, Carla, et al.
Publicado: (2023)

Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections
por: Andeweg, Stijn P., et al.
Publicado: (2022)

Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleases
por: Mock, Ulrike, et al.
Publicado: (2014)

LATE–a novel sensitive cell-based assay for the study of CRISPR/Cas9-related long-term adverse treatment effects
por: Głów, Dawid, et al.
Publicado: (2021)

Structural Evolution of Delta (B.1.617.2) and Omicron (BA.1) Spike Glycoproteins
por: Prandi, Ingrid Guarnetti, et al.
Publicado: (2022)

Identification of Entry Inhibitors against Delta and Omicron Variants of SARS-CoV-2
por: Lee, Richard Kuan-Lin, et al.
Publicado: (2022)

Comparative neutralization profiles of naive and breakthrough infections with Delta, Omicron BA.1 and BA.2 variants of SARS-CoV-2
por: Yang, Yang, et al.
Publicado: (2022)

Prolonged replication of BA.1 and BA.2 Omicron lineages compared to Delta variant in nasopharyngeal samples from COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2023)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants
por: Selvavinayagam, Sivaprakasam T., et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice
por: Baz, Mariana, et al.
Publicado: (2022)

Clonal dynamics studied in cultured induced pluripotent stem cells reveal major growth imbalances within a few weeks
por: Brenière-Letuffe, David, et al.
Publicado: (2018)

Intravitreal Co-Administration of GDNF and CNTF Confers Synergistic and Long-Lasting Protection against Injury-Induced Cell Death of Retinal Ganglion Cells in Mice †
por: Dulz, Simon, et al.
Publicado: (2020)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

The SARS-CoV-2 Delta-Omicron Recombinant Lineage (XD) Exhibits Immune-Escape Properties Similar to the Omicron (BA.1) Variant
por: Arora, Prerna, et al.
Publicado: (2022)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
por: Fehse, Boris, et al.
Publicado: (2020)

Vaccine effectiveness against Delta, Omicron BA.1, and BA.2 in a highly vaccinated Asian setting: a test-negative design study
por: Tan, Celine Y., et al.
Publicado: (2023)

Delta or Omicron BA.1/2‐neutralizing antibody levels and T‐cell reactivity after triple‐vaccination or infection
por: Rose, Ruben, et al.
Publicado: (2022)

Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
por: Hambach, Julia, et al.
Publicado: (2020)

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
por: Pidal, Paola, et al.
Publicado: (2022)

In vitro activity of therapeutic antibodies against SARS-CoV-2 Omicron BA.1, BA.2 and BA.5
por: Touret, Franck, et al.
Publicado: (2022)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f95qg1np6omcouip2ul3qq1als